The role of antimalarial agents in the treatment of SLE and lupus nephritis.
about
Hydroxychloroquine-related retinal toxicityIdentification of activators of ERK5 transcriptional activity by high-throughput screening and the role of endothelial ERK5 in vasoprotective effects induced by statins and antimalarial agentsModelling clinical systemic lupus erythematosus: similarities, differences and success storiesRepositioning: the fast track to new anti-malarial medicines?Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia.Chloroquine cardiomyopathy - a review of the literature.Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery.Hydroxychloroquine Protects against Cardiac Ischaemia/Reperfusion Injury In Vivo via Enhancement of ERK1/2 PhosphorylationSystemic lupus erythematosus in children and adolescents.Unmet medical needs in lupus nephritis: solutions through evidence-based, personalized medicineB-cell selection and the development of autoantibodies.Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9.Effect of hydroxychloroquine and characterization of autophagy in a mouse model of endometriosisChloroquine interference with hemoglobin endocytic trafficking suppresses adaptive heme and iron homeostasis in macrophages: the paradox of an antimalarial agent.The origin and properties of extracellular DNA: from PAMP to DAMP.Life Threatening Severe QTc Prolongation in Patient with Systemic Lupus Erythematosus due to Hydroxychloroquine.Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trialAutophagy inhibition augments resveratrol-induced apoptosis in Ishikawa endometrial cancer cells.Cellular and urinary microRNA alterations in NZB/W mice with hydroxychloroquine or prednisone treatment.Improving outcomes in patients with lupus and end-stage renal disease.Practice guidelines for pharmacists: The pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.Recent progress in the treatment of lupus nephritis.Primary Sjögren syndrome: an update on current pharmacotherapy options and future directions.Lupus nephritis: review of the literature.New insights into the pathogenesis and management of lupus in children.Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases.Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases.Chloroquine-containing compounds: a patent review (2010 - 2014).Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics.The enigma of the clandestine association between chloroquine and HIV-1 infection.Generation of an artificial human B cell line test system using Transpo-mAbTM technology to evaluate the therapeutic efficacy of novel antigen-specific fusion proteins.Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling.Clinical and serological features distinguish patients with incomplete lupus classification from systemic lupus erythematosus patients and controls.Remission and withdrawal of therapy in lupus nephritis.Autophagy in acute brain injury.Glycogen synthase kinase-3 (GSK3) inhibition induces prosurvival autophagic signals in human pancreatic cancer cells.Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles.Implementation of recommendations for the screening of hydroxychloroquine retinopathy: poor adherence of rheumatologists and ophthalmologists.Managing Inflammatory Manifestations in Patients with Chronic Granulomatous Disease.Pregnancy outcome of 126 anti-SSA/Ro-positive patients during the past 24 years--a retrospective cohort study.
P2860
Q26782822-86CDBACB-2347-42E7-AFCC-A259E2DDCC72Q27302392-6A4A0788-44E2-4F6B-B932-252F93D42A56Q28074217-2EB08F6A-FA14-4CE7-92F2-FC5F03E0BB76Q33612012-300F00BE-887F-400C-A8C6-5A0360B4ECA8Q34038766-58BDD5BC-AEB8-48E1-8A59-786612CFDF4EQ34342236-F0792AB7-1DA4-4755-8077-72459A3E0F40Q35148912-5EE38023-9BEB-4DB4-8915-ED5597AA2021Q35860938-34A06614-159F-44FE-930C-8A6A35F01C62Q35947491-EC3C47DF-40E1-4A61-8252-D56558CA915BQ36088877-BBB0C453-6F59-417E-97B0-184CF8B96F62Q36504635-BE333FDC-3C42-4BFC-BC5E-E298821648DAQ36740874-AE72E1FB-5EAF-4FC7-90D3-9A18C40B1438Q36751710-3C3FCDD7-8D88-4F62-B83A-36F1ECB937B4Q36956142-B3734CFC-8AAD-4AB7-8F98-1272C6D4F2A8Q37047827-7D0055FB-4A80-4DB6-8DA7-CBF1FD56D427Q37124633-C3664DBE-936C-4766-B22E-4CEBBB4AF55AQ37267547-309D5260-E823-42F2-BD38-6958B09116A6Q37287535-A3D73D33-71D2-4CBD-A5B6-FA50ACB0E587Q37403811-C1959A94-FB3D-42D1-96C8-A6E2AF4DC23FQ37522782-F6D77948-A3C1-4F5E-8829-FC781D1B9186Q37654774-A94687A8-9D87-4897-860B-1C8AD00900D8Q38010014-4B2A3FCF-764A-40E2-A408-C33B6434CEFAQ38076460-46DD0AC6-9DEB-4B8A-87A5-603FD4725E6CQ38162780-F1CDDD75-E1FD-415B-97E3-63A064D4BA9FQ38192577-20D4C66A-FB1B-4EEE-815E-A41197D7CDC6Q38285841-84B33B5F-754D-4D8A-A8D7-276E616A8F5AQ38360827-B05E546E-6A32-40DE-9BA8-E424D41869E3Q38503439-F485CEC7-857B-4828-BD67-859EE135A7BBQ38557048-8BEF076D-87B9-4A9D-A1F2-56C561EF4EAEQ38559764-F3EAC2F1-CFA6-4912-B226-B816009233A6Q38680881-C02FD481-01BD-40F4-9903-365C7C4F08F4Q38695565-B34BA97B-1B9D-40FF-B308-9FFF0F43897CQ38766335-30BAE320-9BE4-4B8E-B073-DD651995ACE9Q38826018-AB2009D3-0C04-40B2-AD3E-C10868D6506FQ38852246-16CE2FE6-C206-460A-8272-EA95A6E90405Q38922877-8E723FD9-DBCC-4E4C-A8FC-2F07FBA18E41Q39321120-EB71F5EA-6A67-4651-938D-DFCF71AD32D1Q39578523-0510BF85-835B-467E-9590-553D62A56D35Q39684886-52097314-D291-48A7-BF85-34847670A496Q40524514-2073D72F-792D-430F-B089-AC601FABAF84
P2860
The role of antimalarial agents in the treatment of SLE and lupus nephritis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The role of antimalarial agents in the treatment of SLE and lupus nephritis.
@en
The role of antimalarial agents in the treatment of SLE and lupus nephritis.
@nl
type
label
The role of antimalarial agents in the treatment of SLE and lupus nephritis.
@en
The role of antimalarial agents in the treatment of SLE and lupus nephritis.
@nl
prefLabel
The role of antimalarial agents in the treatment of SLE and lupus nephritis.
@en
The role of antimalarial agents in the treatment of SLE and lupus nephritis.
@nl
P2093
P2860
P356
P1476
The role of antimalarial agents in the treatment of SLE and lupus nephritis.
@en
P2093
Earl Silverman
Joanne M Bargman
Senq-J Lee
P2860
P2888
P304
P356
10.1038/NRNEPH.2011.150
P407
P577
2011-10-18T00:00:00Z